MedTrace Logo

Oxaliplatin and Prednisolone (Ox-P) for Patients With Relapsed or Refractory Marginal Zone B-cell Lymphoma(MZL)

NCT01068392 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 42

Last updated 2014-11-04

No results posted yet for this study

Summary

The investigators are willing to investigate the efficacy and safety of oxaliplatin and prednisolone (Ox-P) combination in patients with previously treated MZL who have a few clinical trial data.

Conditions

  • B-cell Lymphomas

Interventions

DRUG

Oxaliplatin, Prednisolone

OXALIPLATIN+PREDNISOLONE (OX-P) D1 Oxaliplatin 130mg/m2 + 5DW 500ml MIV over 2hr D1-5 Prednisolone 40-30-30 mg/day P.O every 3 weeks

Sponsors & Collaborators

  • Samsung Medical Center

    collaborator OTHER

  • Asan Medical Center

    collaborator OTHER

  • Chung-Ang University

    collaborator OTHER

  • Kyungpook National University Hospital

    collaborator OTHER

  • Chonnam National University Hospital

    collaborator OTHER

  • Korea Cancer Center Hospital

    collaborator OTHER

  • Korea University

    collaborator OTHER

  • Dong-A University Hospital

    lead OTHER

Principal Investigators

  • Cheolwon Suh, M.D., Ph.D. · Asan Medical Center

  • Sung Yong Oh, M.D., Ph.D. · Dong-A University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-10-31
Primary Completion
2013-09-30
Completion
2014-09-30

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01068392 on ClinicalTrials.gov